Alex Blyth

Founder & Chief Executive Officer • LIfT BioSciences

Alex founded LIfT BioSciences in 2016 after losing his mother to pancreatic cancer and seeing a new way to revolutionise cancer treatment. He is a serial entrepreneur, inventor, economist & biologist with 20 years’ experience in disruptive healthcare. Alex helped to bring to market multiple first-in-class biopharma drugs including T-Vec the first oncolytic vaccine, Erbitux the first cancer drug to use a genetic test to guide use and Abraxane, one of the few drugs licensed for pancreatic cancer in the last decade.   

Also speaking

Jordan Schecter

Vice President, Clinical Development Cellular Therapy Program • Janssen

Rafiq Hasan

Chief Executive Officer • Complement Therapeutics

Hans Preusting

Co-Founder • DegenRx B.V

Event Info


Innovation Zone

Find out more about the Innovation Zone at Advanced Therapies Europe.

Advanced Therapies Investment Summit

Find out more about the Investor Pre-Day taking place 10th September 2024.